WSO - April 2024 - 421

Schmidt et al.
421
the risk of stroke recurrence and death in patients with insulin
resistance. J Stroke Cerebrovasc Dis 2022; 31: 106744.
3. De Havenon A, Sharma R, Falcone GJ, Prabhakaran S and
Sheth KN. Effect of intensive blood pressure control on incident
stroke risk in patients with mild cognitive impairment.
Stroke 2022; 53: e242-e245.
4. Kwan A, Wei J, Dowling NM, Power MC and Nadareishvili
Z. and SPS3 Study Group Cognitive impairment after lacunar
stroke and the risk of recurrent stroke and death. Cerebrovasc
Dis 2021; 50: 383-389.
5. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after
ischemic stroke or transient ischemic attack. N Engl J Med
2016; 374: 1321-1331.
6. Furie KL, Viscoli CM, Gorman M, et al. Effects of pioglitazone
on cognitive function in patients with a recent ischaemic
stroke or TIA: a report from the IRIS trial. J Neurol Neurosurg
Psychiatry 2018; 89: 21-27.
7. Putter H, Sasako M, Hartgrink HH, Van de Velde CJH and Van
Houwelingen JC. Long-term survival with non-proportional
hazards: results from the Dutch Gastric Cancer Trial. Stat Med
2005; 24: 2807-2821.
8. Chi NF, Chien LN, Ku HL, Hu CJ and Chiou HY. Alzheimer
disease and risk of stroke: a population-based cohort study.
Neurology 2013; 80: 705-711.
9. Zhang WY, Schwartz EA, Permana PA and Reaven PD.
Pioglitazone inhibits the expression of inflammatory cytokines
from both monocytes and lymphocytes in patients with
impaired glucose tolerance. Arterioscler Thromb Vasc Biol
2008; 28: 2312-2318.
10. Rostamian S, Mahinrad S, Stijnen T, Sabayan B and De Craen
AJ. Cognitive impairment and risk of stroke: a systematic
review and meta-analysis of prospective cohort studies. Stroke
2014; 45: 1342-1348.
11. De Havenon A, Smith EE, Sharma R, et al. Improvement in
the prediction of cerebrovascular events with white matter
hyperintensity. J Am Heart Assoc 2023; 12: e029374.
12. Nissen SE and Wolski K. Effect of rosiglitazone on the risk of
myocardial infarction and death from cardiovascular causes.
N Engl J Med 2007; 356: 2457-2471.
13. Bouhlel MA, Derudas B, Rigamonti E, et al. PPAR-gamma
activation primes human monocytes into alternative M2 macrophages
with anti-inflammatory properties. Cell Metab 2007;
6: 137-143.
14. Grambsch PM and Therneau TM. Proportional hazards tests
and diagnostics based on weighted residuals. Biometrika
1994; 81: 515-526.
15. Fu C, Jin X, Chen B, et al. Comparison of the Mini-Mental
State Examination and Montreal Cognitive Assess ment executive
subtests in detecting post-stroke cognitive impairment.
Geriatr Gerontol Int 2017; 17: 2329-2335.
16. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective
associations of fasting insulin, body fat distribution, and diabetes
with risk of ischemic stroke. The Atherosclerosis Risk
in Communities (ARIC) Study Investigators. Diabetes Care
1999; 22: 1077-1083.
17. Hong S, Han K and Park CY. The insulin resistance by triglyceride
glucose index and risk for dementia: population-based
study. Alzheimers Res Ther 2021; 13: 9.
International Journal of Stroke, 19(4)
WSO - April 2024

Table of Contents for the Digital Edition of WSO - April 2024
